Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · USD

$40.5

+0.94 (+2.4%)· Recorded snapshot

Market cap	4.4B
Net income (ttm)	-197.2M
EPS (ttm)	-$1.85
Shares out	108.6M
P/E (forward)	45.3x
Volume	1,314,599
Beta	0.36

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -197.2M
EPS (ttm): -$1.85
P/E (forward): 45.3x
Market cap: 4.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E45.3

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-38

P25 n/aP50 n/aP75 n/a

ROIC-26.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EWTX indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001710072
Company name	Edgewise Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	28036F105
Earnings date	2026-11-09
Earnings time	bmo
Employees	127
Employees change	1
Employees growth	0.79%
Enterprise value	$3.9B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-03-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US28036F1057
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4.4B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$40.47
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	EWTX
U.S. state	Colorado
Website	https://edgewisetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.57%
FCF / EV yield	-4.07%
FCF yield	-3.64%
Forward EV/Sales	30.29x
Forward P/E	45.26x
Forward P/S	33.83x
P/B ratio	9.51x
Price / tangible book value	9.73x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.6M
ROA	-25.03%
ROA (5Y)	-18.79%
ROCE	-48.57%
ROE	-38.03%
ROE (5Y)	-28.36%
ROIC	-26.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-454,000
Depreciation and amortization	$2.1M
EBIT	$-218.9M
EBITDA	$-216.8M
EPS	$-1.85
FCF per share	$-1.46
Financing cash flow	$20.9M
Free cash flow	$-158.8M
Free cash flow minus SBC	$-194.9M
Investing cash flow	$166.4M
Net cash flow	$28.9M
Net income	$-197.2M
Operating cash flow minus SBC	$-194.4M
Operating income	$-218.9M
Stock-based compensation	$36M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.16
Debt / equity	0.01
Long-term assets	$8.2M
Long-term liabilities	$2.6M
Net cash (debt)	$457.1M
Net cash / market cap	10.49%
Net cash growth	-22.47%
Net debt / equity	-1.02
Piotroski F-Score	1
Property, plant and equipment	$8.2M
Shareholders' equity	$448.1M
Tangible book value	$448.1M
Tangible book value per share	$4.16
Total assets	$479.7M
Total cash	$460.7M
Total debt	$3.6M
Total liabilities	$31.6M
WACC	6.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$471.5M
Current liabilities	$29M
Current ratio	16.24
Net working capital	$-17.2M
Quick ratio	15.86
Working capital	$442.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-9.7%
Dividend yield	0%
Shareholder yield	-9.7%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$38.43
1D price change	2.38%
1M price change	1.77%
1M total return	1.77%
1W price change	0.72%
1W total return	0.72%
1Y price change	149.75%
1Y return CAGR	149.91%
1Y total return	149.75%
20-day SMA	$39.13
200-day SMA	$36.15
3M price change	-3.76%
3M total return	-3.76%
3Y price change	540.56%
3Y return CAGR	85.69%
3Y total return	540.56%
50-day SMA	$41.57
50-day SMA vs 200-day SMA	50over200
52-week high	$48.51
52-week high date	2026-09-17
52-week low	$15.66
52-week low date	2025-10-28
5Y price change	147.13%
5Y return CAGR	19.84%
5Y total return	147.13%
6M price change	30.66%
6M total return	30.66%
All-time high	$48.51
All-time high date	2026-09-17
All-time low	$5.12
All-time low date	2023-11-10
Average true range (ATR)	$1.84
Average volume	1.4M
Beta (1Y)	1.08
Beta (2Y)	1.72
Beta (5Y)	0.36
Change from 52-week high	-16.57%
Change from 52-week low	158.43%
Change from all-time high	-17.47%
Change from all-time low	681.93%
Change from open	3.53%
Day's gap	-1.11%
Dollar volume	$53.2M
High price	$40.50
Low price	$39.09
Monthly RSI	68.23
Open price	$39.09
Position in 52-week range	97.87%
Premarket change	0.46%
Premarket close	$39.53
Premarket price	$39.71
Previous close	$39.53
Price vs 150-day SMA	4.18%
Price vs 20-day SMA	2.32%
Price vs 200-day SMA	10.75%
Price vs 50-day SMA	-3.69%
Relative volume	0.95
Return from IPO open	48.67%
Return from IPO price	150.88%
RSI	50.81
Sharpe ratio	1.54
Sharpe ratio (3Y)	1.06
Sharpe ratio (5Y)	0.55
Sortino ratio	3.03
Sortino ratio (3Y)	2
Sortino ratio (5Y)	0.98
Volume	1.3M
Weekly RSI	53.45
YTD price change	61.33%
YTD total return	61.33%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	74.3M
Float percentage	68.38%
Shares change (QoQ)	0.52%
Shares change (YoY)	9.7%
Shares held by insiders	0.19%
Shares held by institutions	80.38%
Shares outstanding	108.6M
Short % of float	15.11%
Short % of shares	10.34%
Short ratio	6.9 days

Deeper analysis on EWTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EWTX report

Is a complete EWTX research report available?

No complete published report is available for Edgewise Therapeutics, Inc. (EWTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Edgewise Therapeutics, Inc. (EWTX)

Price

Financial snapshot

Fair-value bridge

Latest news · EWTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EWTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EWTX

Frequently asked questions